Skip to Content
Morningstar

Janus Henderson Global Life Sciences S JFNSX

Morningstar Medalist Rating
Medalist Rating as of | See Janus Henderson Investment Hub
  • NAV / 1-Day Return 66.51  /  −0.64 %
  • Total Assets 5.4 Bil
  • Adj. Expense Ratio
    1.180%
  • Expense Ratio 1.180%
  • Distribution Fee Level Above Average
  • Share Class Type No Load
  • Category Health
  • Investment Style Large Growth
  • Min. Initial Investment 2,500
  • Status Open
  • TTM Yield —
  • Turnover 34%

USD | NAV as of Apr 18, 2024 | 1-Day Return as of Apr 18, 2024, 11:21 PM GMT+0

Morningstar’s Analysis JFNSX

Will JFNSX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable JFNSX’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the JFNSX management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of JFNSX’s parent organization’s priorities and whether they’re in line with investors’ interests.

Janus Henderson Global Life Sciences S's Average Process Pillar and People Pillar ratings result in a Morningstar Medalist Rating of Neutral.

null Morningstar Manager Research

Morningstar Manager Research

Summary

Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-highest quintile among peers.

by Morningstar Manager Research
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings JFNSX

More JFNSX Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 37.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Eli Lilly and Co

6.63 346.8 Mil
Healthcare

UnitedHealth Group Inc

5.96 311.6 Mil
Healthcare

Novo Nordisk A/S Class B

4.81 251.3 Mil
Healthcare

Merck & Co Inc

3.56 186.1 Mil
Healthcare

AstraZeneca PLC

3.56 186.0 Mil
Healthcare

AbbVie Inc

3.21 168.0 Mil
Healthcare

Abbott Laboratories

2.49 129.9 Mil
Healthcare

Sanofi SA

2.46 128.7 Mil
Healthcare

Vertex Pharmaceuticals Inc

2.37 124.1 Mil
Healthcare

Boston Scientific Corp

2.29 119.5 Mil
Healthcare